EMEA-002016-PIP03-19-M02
Key facts
Invented name |
Piqray
|
Active substance |
Alpelisib
|
Therapeutic area |
Other
|
Decision number |
P/0412/2022
|
PIP number |
EMEA-002016-PIP03-19-M02
|
Pharmaceutical form(s) |
|
Condition(s) / indication(s) |
Treatment of PIK3CA related overgrowth spectrum
|
Route(s) of administration |
Oral use
|
Contact for public enquiries |
Novartis Europharm Limited
E-mail: paediatric.enquiries@novartis.com |
Decision type |
PM: decision on the application for modification of an agreed PIP
|